Earnings Releases·Nov 12, 2026, 4:02 PM ET

Heartflow — Third Quarter 2026 Earnings Summary

Total revenue reached $72.9 million, a 57% year-over-year increase, with U.S. revenue up 60% to $67.9 million; gross margin expanded to 83.6% from 76.5% in the prior year period.
Net loss narrowed to $11.5 million ($0.13 per share) from $50.9 million in the prior year, while non-GAAP net loss improved to $2.7 million ($0.03 per share) from $13.2 million.
Full-year 2026 total revenue guidance was raised to $262 million–$264 million (implying 49%–50% growth) and non-GAAP gross margin guidance increased to approximately 82.5%.
Revenue growth was driven by increased U.S. FFR_(CT) and Plaque Analysis case volumes, with Plaque Analysis activations ramping ahead of plan across a widening share of applicable CCTAs.
The company maintains a strong liquidity position with $253.0 million in cash, equivalents, and investments, while technology adoption has reached over 1,800 institutions globally.